SCHEMBL21458417

SCHEMBL21458417

CCOC(=O)COC[C@H](NC(=O)OC(C)(C)C)c1ccc(Br)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TSHR P16473 1/20 0.42
AAK1 Q2M2I8 3/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
CTSS P25774 1/20 0.40
CTSK P43235 1/20 0.40
CACNA1B Q00975 1/20 0.40
NPC1 O15118 1/20 0.40
RECQL P46063 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TP53 P04637 1/20 0.39
PTPRB P23467 1/20 0.37
PTPN1 P18031 1/20 0.37
PPARA Q07869 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21458419 1.00 MAPT (0.47) MAPTALDH1A1TSHRAAK1CYP1A2
SCHEMBL17844760 0.90 TSHR (0.48) MAPTALDH1A1TSHRCYP1A2CYP2C9
SCHEMBL21458427 0.86 CTSS (0.46) MAPTALDH1A1AAK1CTSSCTSK
SCHEMBL21458426 0.86 CTSS (0.46) MAPTALDH1A1AAK1CTSSCTSK
SCHEMBL26932275 0.86 TSHR (0.40) MAPTALDH1A1TSHRCYP1A2CYP2C9
SCHEMBL12733028 0.85 SMN1; SMN2 (0.46) ALDH1A1TSHRSMN1; SMN2PTPN1MAPK1
SCHEMBL30683042 0.82 TSHR (0.42) MAPTALDH1A1TSHRCYP1A2CYP2C9
SCHEMBL26932080 0.82 TSHR (0.42) MAPTALDH1A1TSHRCYP1A2CYP2C9
SCHEMBL2634242 0.82 MAPT (0.46) MAPTALDH1A1TSHRAAK1CYP1A2
SCHEMBL29373349 0.82 MAPT (0.46) MAPTALDH1A1TSHRAAK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552783-B2 Modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-17 US disclosed
WO-2023239645-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
WO-2023239645-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
US-20220402907-A1 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE YALE UNIVERSITY 2022-12-22 US disclosed
US-11161841-B2 Modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2021-11-02 US disclosed
EP-3774777-A2 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2021-02-17 EP disclosed
CN-112218859-A Modulators of proteolysis and related methods of use 阿尔维纳斯运营股份有限公司 2021-01-12 CN disclosed
US-20190315732-A1 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315732-A1 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE MDM2, CRBN, VHL MAPT 3018/4885ALDH1A1 2958/4885TSHR 4501/4885
US-20220402907-A1 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE MDM2, CRBN, VHL MAPT 3018/4885ALDH1A1 2958/4885TSHR 4501/4885
US-12552783-B2 Modulators of proteolysis and associated methods of use CRBN, ADRM1, MDM2 MAPT 3054/4885ALDH1A1 3965/4885TSHR 2253/4885
US-11161841-B2 Modulators of proteolysis and associated methods of use MDM2, CRBN, VHL MAPT 3018/4885ALDH1A1 2958/4885TSHR 4501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.